Short Interest in Vaccinex Inc (NASDAQ:VCNX) Expands By 40.7%

Share on StockTwits

Vaccinex Inc (NASDAQ:VCNX) saw a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 40,800 shares, a growth of 40.7% from the July 15th total of 29,000 shares. Currently, 1.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 530,300 shares, the days-to-cover ratio is presently 0.1 days.

In other news, Director Albert Friedberg bought 1,126,760 shares of the business’s stock in a transaction on Friday, July 10th. The stock was acquired at an average price of $3.55 per share, with a total value of $3,999,998.00. Following the completion of the purchase, the director now directly owns 439,555 shares in the company, valued at $1,560,420.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 68.60% of the company’s stock.

VCNX traded down $0.17 during trading on Friday, hitting $5.53. 1,493 shares of the stock traded hands, compared to its average volume of 221,863. The firm has a market capitalization of $112.93 million, a P/E ratio of -3.13 and a beta of 1.64. The firm has a 50-day moving average of $5.75 and a 200 day moving average of $4.70. Vaccinex has a 12-month low of $3.22 and a 12-month high of $12.23.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Vaccinex from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Oppenheimer reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Vaccinex in a research note on Monday.

About Vaccinex

Vaccinex, Inc, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease.

Recommended Story: Trade War

Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with's FREE daily email newsletter.

Leave a Reply